| Flecainide and encainide. | |
| | |
MedLine Citation:
|
PMID: 3107989 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Flecainide and encainide (class IC) are presently under clinical evaluation in Italy. They prolong the duration of the QRS but not the period of ventricular repolarisation: the prolongation of QT is due solely to the prolongation of the Q-J. Flecainide and encainide are extremely powerful and are suitable for the treatment of reciprocating supraventricular paroxysmal tachycardia and of persistent reciprocating tachycardia, the prophylaxis of WPW atrial fibrillation including cases with a short anterograde refractory period of the anomalous pathway and the treatment of ventricular ectopic beats and ventricular tachycardia. Both drugs are probably effective for the treatment of atrial fibrillation. However, in the case of atrial flutter they are of little effect of sinus rhythm cardioversion; on the other hand they significantly prolong the duration of the A-A interval, with variable results on ventricular rate. Flecainide and encainide have 'parodoxical' arrhythmogenic effects, related to administration dosages, severity of the arrhythmia and seriousness of cardiopathy. Encainide shows peculiar pharmacokinetics due to hepatic oxidating metabolisation and to production of metabolites; among these the O-demethylencainide and the 3-methoxy-O-demethylencainide have an antiarrhythmic activity, which is probably more important than the encainide parent and is longer-lasting. There are 'extensive', 'poor' and 'non-metaboliser' subjects. This results in wide pharmacokinetic inter- and intraindividual variability which must be taken into account during clinical treatment.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
F Furlanello; G Vergara; R Bettini; G Mosna; L Gramegna; M Disertori |
Related Documents
:
|
3675859 - Long-term intracoronary ethanol administration electrophysiologic and morphologic effects. 7534809 - Paroxysmal supraventricular tachycardia initiated by ventricular couplets in concealed ... 12897989 - Adult presentation of mcad deficiency revealed by coma and severe arrythmias. 1598859 - Long term ecg recording with holter monitoring in clinically healthy horses. 534589 - Retrograde catheterisation of left atrium. 3682189 - Swallowing-induced paroxysmal supraventricular tachycardia. 23523189 - Left ventricular myocardial contractility is depressed in the borderzone after posterol... 18070299 - Left ventricular endocardial pacing: a transarterial approach. 19678719 - Measurements of valve circumferences and ventricular wall of fetal hearts in chile. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: European heart journal Volume: 8 Suppl A ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 1987 Mar |
Date Detail:
|
Created Date: 1987-07-14 Completed Date: 1987-07-14 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 33-40 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anilides
/
pharmacology,
therapeutic use* Anti-Arrhythmia Agents / pharmacology, therapeutic use* Arrhythmias, Cardiac / drug therapy* Encainide Flecainide / pharmacology, therapeutic use* Humans |
| Chemical | |
Reg. No./Substance:
|
0/Anilides; 0/Anti-Arrhythmia Agents; 54143-55-4/Flecainide; 66778-36-7/Encainide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Par...
Next Document: Studies on diphosphonate kinetics. Part I: Evaluation of plasma elimination curves during 24 h.